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Hematopoiesis arguably provides the most well-defined role of stem cells in tissue development,
maintenance, and repair, largely because of the experimental methods developed over decades of
investigation. Assays of hematopoietic stem and progenitor cell potential were developed in the
late 1950s–1960s with the first reports of in vivo transplantation into lethally irradiated recipients
(Ford et al., 1956; McCulloch and Till, 1960) and clonal growth of hematopoietic bone marrow cells
in vitro (Bradley and Metcalf, 1966). These two major assays have undergone substantial refinement
but remain the foundation for defining hematopoietic stem cell biology. Here, we provide a brief
overview of methods commonly used to analyze hematopoietic stem and progenitor cell content
in mice, discuss the limitations of these assays, and provide an in-depth review of the limiting dilution
assay (Szilvassy et al., 1990), the best single assay for quantitating HSC content.Introduction
All blood cells are derived from hematopoietic stem cells
(HSCs), which are multipotent cells that under permissive
conditions are capable of either self-renewal (hence form-
ing another HSC) or differentiation into all blood cell
lineages. Hematopoiesis is now among the best-defined
differentiation cascades in mammalian tissues due to the
ease of access and morphologic distinctiveness of many
of its members. The advent of antibody technology, cul-
ture capability, transplantation, and finally genetic engi-
neering of mice has enabled a detailed understanding of
processes involved in the commitment and differentiation
of HSCs into progenitor cells and ultimately mature blood
cells. Furthermore, combining antibody-based subselec-
tion of cells with transplantation has made possible the
identification of progenitors andHSCs. A range of different
methods for characterizing stem and progenitor cell pop-
ulations are now available for use in hematopoietic cell
research. A review and commentary of these methods
seems fitting for a new journal in the stem cell field. This
review will focus on techniques applied tomurine hemato-
poiesis, with a particular emphasis on analyzing HSC
content in mutant mice or in non-steady-state conditions.
Surrogate Short-Term In Vivo and In Vitro Assays
for Detecting HSCs and Their Progeny
Often the first steps many investigators take toward ana-
lyzing hematopoietic cell content in mice involve short-
term assays. These studies provide much quicker results
than the long-term repopulating HSC assay, providing
data on either the day of analysis or within a couple of
weeks of initiating experiments. Such studies can be use-
ful screens to determine whether it is worthwhile perform-
ing long-term repopulating HSC assays, which not only
require patience due to the length of time required tomon-itor the mice posttransplant but require significant num-
bers of experimental animals and are consequently costly.
The caveat to using the majority of these short-term stud-
ies is that, while informative, these assays do not measure
HSCs and may not provide information that corresponds
to the quality or quantity of HSCs in the sample studied.
Examples of routinely used surrogate methods for screen-
ing HSCs and progenitor cells follow.
Immunophenotypical Analysis of HSC/Progenitors
In the last 20 years, a number of different methods
whereby HSCs and progenitor cells can be identified
have emerged (Goldschneider et al., 1978; Spangrude
et al., 1988; Visser and Bol, 1982; Visser et al., 1981). All
rely on fluorescence-activated cell sorting (FACS)-based
methods. The purity of the populations of HSCs achieved
using these methods has increased within recent years,
such that approximately 50%–96% of single cells in
certain purified populations can give rise to long-term
reconstitution after transplantation (Matsuzaki et al.,
2004; Yilmaz et al., 2006). The most commonly used
FACS-purified populations of HSC/progenitor cells
include the following:
Thy1.1lo, Lin Sca-1+ Cells
The Weissman laboratory has been a driving force in de-
fining methods for the purification of HSCs by FACS, pro-
viding the first evidence in 1988 that short-term repopulat-
ing HSCs (as opposed to FACS methods isolating CFU-S
[Goldschneider et al., 1978; Visser and Bol, 1982]) could
be isolated based on their expression of stem cell anti-
gen-1 (Sca-1), low expression of Thy1.1, and lack of
expression of lineage markers (Spangrude et al., 1988).
The same population was shown to contain long-term re-
populating HSCs in a subsequent study (Uchida and
Weissman, 1992). These Thy1.1lo, lineage-negative (lin)Cell Stem Cell 1, September 2007 ª2007 Elsevier Inc. 263
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groups internationally. The population was further purified
by the expression of the stem cell factor receptor, c-Kit, in
1992 (Ikuta andWeissman, 1992). However, there are lim-
itations of using this population in research laboratories:
Thy1.1 is expressed by the C57BL/Ka-Thy1.1 mice, but
not C57BL/6 mice, which are the congenic strain of mice
most commonly used for HSC transplantation studies
worldwide (Spangrude and Brooks, 1992). Furthermore,
the Thy1.1 counterpart in C57BL/6 mice (Thy1.2) does
not have the same pattern of expression on HSCs as
does Thy1.1 (Spangrude and Brooks, 1992).
Lin c-Kit+ Sca-1+ Cells
The expression of c-Kit on hematopoietic progenitor cells
was first described by Ogawa et al. in 1991 (Ogawa et al.,
1991). In 1992, Suda’s laboratory reported the isolation of
HSCs from C57BL/6 mice in the lin c-Kit+, Sca-1+
(LKS+) population, verifying that a similar protocol to
that described by Weissman’s lab (Ikuta and Weissman,
1992) did enrich for HSCs in this congenic mouse strain
(Okada et al., 1992). However, this population is very
heterogeneous and consists predominantly of progenitor
cells with less than 10% of it representing HSCs. More re-
cently, the expression of CD34 (Osawa et al., 1996) and
Flt3 (CD135) (Adolfsson et al., 2001; Yang et al., 2005)
has been used to further purify long-term repopulating
HSCs (LKS+ CD34 Flt3) from short-term repopulating
HSCs (LKS+ CD34+ Flt3) and multipotent progenitors
(LKS+ CD34+ Flt3+) (Yang et al., 2005).
Common problems associated with these methods
include the restriction of the use of Sca-1 to certain strains
of mice (Spangrude and Brooks, 1993) and discrepancies
between the expression of these antigens and their func-
tional potential in older mice, in HSCc in different stages of
the cell cycle, post-5-FU or G-CSF treatment and post-
transplantation (Morrison et al., 1996; Spangrude et al.,
1995; Walkley et al., 2005b). Moreover, the expression
of CD34 can depend upon the developmental stage of
the mouse, as CD34 is expressed on HSCs of mice youn-
ger than 8 weeks (Matsuoka et al., 2001). Reliability of
these markers is also questionable in mutant mice, as
the phenotype of HSCs in such mice has been shown to
not always correlate with the numbers or quality of
HSCs when they are measured using more stringent func-
tional studies (Purton et al., 2006; Walkley et al., 2005a,
2007b). Caution should therefore be used when relying
on these markers to assay HSC content in non-steady-
state or mutant mouse models.
Fluorescent Dyes Capitalizing on High Drug Efflux
Properties of HSCs: Rhodamine 123, Hoescht
33342, and the Side Population
Two different vital dyes, the mitochondrial-binding dye
rhodamine 123 (Rh123) and DNA-binding dye Hoescht
33342 (Ho 33342), have also been used either alone or in
combination to isolate HSCs (Goodell et al., 1996; Li and
Johnson, 1992; McAlister et al., 1990; Phillips et al.,
1992; Wolf et al., 1993). Both of these dyes are retained
at very low intensity in HSCs due to high efflux of the
dyes from HSCs, as shown by studies utilizing the drug264 Cell Stem Cell 1, September 2007 ª2007 Elsevier Inc.verapamil. This drug blocks the activity of the ATP-binding
cassette (ABC) transporter superfamily (membrane
pumps that efflux drugs from cells and are highly
expressed in HSCs) and prevents both of these dyes
from being effluxed, resulting in the disappearance of
the low-retaining Rh123 and Ho 33342 populations
(Goodell et al., 1996; Phillips et al., 1992).
A more common method used in laboratories today to
isolate HSCs is the Ho 33342 side population (SP) (Good-
ell et al., 1996). The SP cells are visualized by emitting Ho
33342 at two wavelengths simultaneously, resulting in
a distinct ‘‘tail’’ profile, which disappears with verapamil
treatment (Goodell et al., 1996). The major problem with
this method is that it is highly sensitive to slight modifica-
tions in staining techniques, hence leading to discrep-
ancies in the quality of the HSC populations obtained
using this method in different laboratories (Lin and Good-
ell, 2006). Furthermore, different batches of Ho 33342
have been reported to vary significantly in their ability to
accurately delineate the SP population; hence they need
to be screened to select a suitable batch for experiments
(Matsuzaki et al., 2004). The SP population is also not as
pure as HSCs enriched by other methods such as LKS+
CD34 Flt3 cells, although it can be used in combination
with other markers such as Sca-1, c-Kit, and CD34 to fur-
ther purify HSCs with extreme efficiency (Lin and Goodell,
2006; Matsuzaki et al., 2004). Notably, cells with an SP
profile have also been detected in many other organs
but with inconsistent functional correlation with stem
cell-like functions (Challen and Little, 2006). This method
should not be assumed to yield stem cells in other tissue
types or even in species other than the mouse.
SLAM Family Members
SLAM proteins are a family of cell surface glycoproteins in
the immunoglobulin superfamily with specific SLAM
antigens (CD150+ CD244 CD48 cells) identified as
useful to purify a population of which approximately
50% of single cells reconstituted lethally irradiated
animals (Kiel et al., 2005). Unlike the limitations presented
by those isolated using Thy1.1 or Sca-1 expression, the
SLAM receptors appear to be expressed by many mouse
strains (Kiel et al., 2005), and more faithfully detect HSCs
in older, mobilized, or transplanted mice (Yilmaz et al.,
2006). The SLAM method for isolating HSCs is yet to be
tested in mutant mice to prove this population accurately
detects HSCs in such mice. Regardless, the functional
potential of HSCs and progenitors cannot be measured
merely based on surface expression markers; hence,
where possible, investigators should not rely solely on
immunophenotypical analysis to measure HSC content
in mice.
In Vitro and Short-Term In Vivo Assays
for Detecting Functional Potential of HSCs
and Progenitors
In vitro and short-term in vivo assays are also often used
for measuring HSC and progenitor cell content but are
generally a reflection of the more mature progenitor cells
as opposed to the immature HSCs.
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The colony-forming cell (CFC) assays measure progenitor
cells in a given population using semisolid agar- or, more
commonly, well-defined methylcellulose-based culture
media, which are commercially available. The majority of
CFCs consist of lineage-restricted colonies: erythroid-
restricted burst-forming units-erythroid (BFU-E), which
are more immature than the colony-forming units-
erythroid (CFU-E); megakaryocyte-restricted CFU-Mk;
colony-forming units-granulocytes (CFU-G), colony-form-
ing units-monocytes/macrophages (CFU-M); and colony-
forming units-granulocytes/macrophages (CFU-GM). The
most immature (multipotent) CFC measurable contains
granulocytes, erythrocytes, macrophages, and often
megakaryocytes (CFU-GEMM) and is usually measured
at day 12 after culture initiation. This CFC is also often
called CFU-mixed, as it may not always contain megakar-
yocytes but does contain erythroid and granulocyte/mac-
rophage cells. B and T lymphocyte in vitro CFC potential
are more difficult to assess, usually requiring specialized
coculture systems (Schmitt and Zuniga-Pflucker, 2002;
Whitlock and Witte, 1982), and hence are not routinely
used, although there are now commercially available
methylcellulose-based colony assays to measure pre-B
cells. While informative about the progenitor cell content




The cobblestone area-forming cells (CAFC) and long-term
culture-initiating cell (LTC-IC) assays are coculture sys-
tems that some investigators use to predict HSC frequen-
cies. They are described in more detail in a recent review
by van Os et al. (2004). The reliability of the use of these
assays to measure HSCs remains controversial in the
field, though it can fairly be said that they reflect a more
immature or primitive population than the CFC. Another
issue with these assays is the interlaboratory variability
often observed due to varying feeder layers and specific
culture conditions. They may be useful, however, in limit-
ing dilution format for quantitating primitive cells when
other features such as homing capacity or other functions
required for in vivo engraftment may compromise the
reliability of transplant assays.
Short-Term In Vivo Assays
Colony-forming unit-spleen (CFU-S) cells are cells that,
once injected into an irradiated recipient, home to the
spleen and form macroscopic colonies that provide very
short-term (usually 1–3 weeks) in vivo repopulation of
the mouse (Till and McCulloch, 1961). The CFU-S are
therefore early engrafting cells, providing radioprotection
to the mouse and allowing it to survive more readily in
the first 2–3 weeks posttransplantation when pancytope-
nia usually occurs. These progenitors are more immature
than CFCs but are more mature than HSCs.
Investigators should therefore be cautious about their
conclusions regarding HSC content from studies that rely
on the surrogate assays outlined above. The gold standard
for measuring HSCs is the long-term repopulating assay.In Vivo Assays toMeasure HSC Numbers and Their
Functional Potential
There are various types of long-term repopulating assays,
the most common of which is the competitive repopula-
tion assay (Harrison, 1980). This assaymeasures the func-
tional potential of the unknown source of HSCs against
a set known number of HSCs (usually whole bone marrow
cells from congenic wild-typemice). In brief, the number of
repopulating units (RU) in the donor cell population
(source of unknown HSC content being measured) can
be determined by the following formula: donor RU = %
donor cells 3 C/(100  % donor cells), where C = the
number of competing RU and 13 105 whole bonemarrow
cells = 1 competing RU (Harrison et al., 1993; Yuan et al.,
2005). While providing information about the function of
HSCs in their capacity to repopulate compared to the
competing bone marrow, this study provides qualitative
or at best semiquantitative information about the HSCs
within a given population—it cannot distinguish between
the number of HSCs or their quality (progeny produced
per HSC). Furthermore, caution should be used when de-
signing competitive repopulation assays, as it has been
shown that the reliability of this assay is critically depen-
dent on the numbers of HSCs present in the populations
being assessed: when too few or too many HSCs (recipi-
ents of <13 105 or >23 107 bone marrow cells each from
donor and competing sources) are present, the data may
not be meaningful (Harrison et al., 1993).
The frequency of HSCs (fromwhich the number of HSCs
can be calculated) is commonly measured using the limit-
ing dilution assay, which is a variation of the competitive
repopulation assay. In this assay, a series of dilutions of
the unknown source (donor ‘‘test’’ cells) are competed
against a set number of competing bone marrow cells.
The number of mice negative for reconstitution in each
cell dose is then measured, and the frequency of HSCs
(competitive repopulating units, CRU) is estimated using
Poisson statistics (Szilvassy et al., 1989, 1990; Taswell,
1981). The success of this assay therefore relies on the
survival of the transplanted mice. To achieve statistical
significance, it is best to have at least eight recipient
mice per cell dose, with aminimum of three (but preferably
four or more) cell doses (Szilvassy et al., 1990). Note that
CRU, which measures the quantity of HSCs, is distinct
from RU, which measures the functional quality of HSCs.
To aid in data analysis of limiting dilution assays, StemCell
Technologies Inc. have developed a program, L-Calc, the
software for which is free to download from their website.
This program calculates the frequency of HSCs within the
test cell population, provides the 95% confidence inter-
vals for these calculations, and can also be used to
perform statistical comparison between two or more test
samples.
As will be discussed further below, there are two major
types of limiting dilution assay-based CRU assays
routinely used today to measure HSCs in studies per-
formed by numerous investigators. The major difference
between these assays is the number of HSCs present in
the competing cell source. The first, termed the CRUCell Stem Cell 1, September 2007 ª2007 Elsevier Inc. 265
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HSCs as the competing source of cells. This allows for
the optimal detection of HSCs at the single level but
does not allow for the quality of the HSCs being measured
to be compared to a known standard of wild-type HSCs.
The second assay, also generally termed a CRU assay,
which can create confusion, incorporates a standard,
sufficient number of HSCs in the competing cell popula-
tion. The test cells are therefore measured relative to their
ability to effectively compete against this standard num-
ber of HSCs: if the test cells have fewer or more HSCs
than wild-type control donors, this will generally be
reflected in the results of the assay. The major limitation
of this CRU assay is that it may not accurately detect
HSCs at the single cell level.
The most stringent test of HSC potential is the serial
transplant assay. The HSC compartment has been shown
to be heterogeneous, comprising a hierarchy of HSCs that
can be identified by their functional capacity. Themost im-
mature HSC in this hierarchy is capable of sustaining he-
matopoiesis throughout serial transplantation (Lemischka
et al., 1986b; Purton et al., 2006; Rosendaal et al., 1979).
Hence, in this assay, the source of HSCs is transplanted
into sequential serial transplant recipients, and the ability
of this population to sustain hematopoiesis by presump-
tive self-renewing divisions is determined. Limitations to
this assay are its dependence upon homing and engraft-
ment processes that may be perturbed without altering
stem cell function per se, in particular mutant mouse
strains. Therefore, serial dilution is most useful where
homing and engraftment are not affected. Duration of
engraftment, a process that over prolonged intervals
requires stem cell self-renewal, may be considered an
alternative measure of stem cell function in contexts
where homing or engraftment may be altered.
The limiting dilution assay utilizing bone marrow cells
containing a sufficient, standard number of HSCs (such
as 23 105 bone marrow cells) can be used to incorporate
all three different types of long-term repopulating HSC
assays. If the competing cells are whole bone marrow
cells, the numbers of RUs can be measured for each of
the test cell doses injected. Furthermore, secondary
transplants can be performed after the primary transplant
has been monitored long-term. There are, however, some
important factors critical to the analysis of the data in
limiting dilution assays, which, if not standard across
laboratories, can lead to discrepancies in the results
obtained. These include the source of competing cells,
the source of donor cells, the percent cutoff used to deter-
mine the frequencies of negative mice, and the time post-
transplant at which the data are analyzed. We discuss
these below.
Important Factors to Consider in Limiting
Dilution Assays
Competing Cells
The source of competing cells is a variability that can lead
to different results between laboratories. Initially, Szil-
vassy et al. used compromised bone marrow as the266 Cell Stem Cell 1, September 2007 ª2007 Elsevier Inc.competing source for the CRU transplants (Szilvassy
et al., 1990). This population was obtained by serially
transplanting bone marrow into lethally irradiated recipi-
ents for two successive transplants (Szilvassy et al.,
1990). Problems associated with this method were the
cost and time required to obtain the compromised bone
marrow, and the possibility of variability between different
populations of compromised bone marrow. In addition,
this population of competing cells was depleted of HSCs
and hence did not provide a good source of known HSC
content for competitive reconstitution.
The use of compromised bone marrow for competing
cells was subsequently replaced by the use of W41/W41
mice as recipient mice (Miller and Eaves, 1997; Trevisan
et al., 1996). The hematopoietic cells (including HSCs) of
W41/W41 mice have a mutated c-Kit gene, resulting in
partial impairment of their c-Kit receptor kinase activity
(Nocka et al., 1990). The hematopoietic cells of these
mice therefore do not have a normal response to the c-Kit
ligand, stemcell factor,which isproducedby thebonemar-
row microenvironment and so exhibit reduced numbers of
HSCs (Geissler and Russell, 1983; Reith et al., 1990).
CRU studies performed by Trevisan et al. (1996) demon-
strated that sublethally irradiated W41/W41 mice provide
amore sensitive host environment whereby small numbers
of HSCs could be reliably detected without the need for
additional support marrow to be provided to the recipients.
More recently, investigators have used whole bone
marrow cells from mice that have not been previously
transplanted for their competing cells, which is a method
that is more reproducible between laboratories and allows
for a direct comparison of the quality and quantity of
HSCs, such as when comparing HSC number and func-
tion in mutant versus wild-type mice. In our laboratories,
we have found that 23 105 competing bone marrow cells
have provided a good standard of competing marrow for
limiting dilution assay studies (Janzen et al., 2006; Purton
et al., 2006; Walkley et al., 2005a). This finding has also
been independently confirmed in studies from at least
three other laboratories (Ema et al., 2005; Lawrence
et al., 2005; Liang et al., 2007). In each of these studies,
the data obtained were a good fit to the Poisson distribu-
tion and independently determined that the number of
long-term multilineage repopulating HSCs per 1 3 105
wild-type bone marrow cells was approximately three to
four, a finding also consistent with that reported by others
using various means (Abkowitz et al., 2000).
Test Cells, Unknown HSC Potential
As for the competing cells, the source of test cells is also
an important factor to consider when designing a limiting
dilution assay. An example is single LKS+ CD34 cells,
which were previously transplanted together with LKS+
CD34+ cells, a population enriched for short-term repopu-
lating HSCs but devoid of long-term repopulating HSCs
(Osawa et al., 1996). More recently Ema et al. transplanted
single LKS+CD34 cells together with 23 105 competitor
bone marrow cells and assessed their multilineage com-
petitive reconstituting ability (Ema et al., 2005, 2006). In
each of two different experiments, they reported that 24
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reconstitution at 16 or 12 weeks posttransplant, respec-
tively. These values equate to 75% or 64% of mice in
each group being negative for engraftment, which is
outside the range of the 37% negative mice value required
to calculate one HSC using Poisson statistics (Szilvassy
et al., 1990). It is therefore possible that the sufficient
numbers of HSCs within 2 3 105 competing whole bone
marrow cells could mask the repopulating potential of
the single test HSCs coinjected. In this instance, the use
of the W41/W41 recipient-based CRU may provide
a more sensitive means of HSC detection.
Furthermore, while single cell transplants are important
when testing the ability of new strategies to purify HSCs,
the use of immunophenotypical methods to isolate
HSCs for comparative studies may not provide accurate
results when assessing HSC content in mutant mouse
models (or HSCs that might not otherwise be in a steady
state condition), as discussed earlier in this review. Single
cell studies also require very large numbers of recipient
mice for accurate results (>100 for highly purified HSC
sources, even more for HSC populations that are not as
pure)—such expensive studies are often therefore not
feasible in smaller laboratories that have restricted fund-
ing. A recent study of extensive single cell transplants
performed in combination with serial transplantation has
revealed a previously unappreciated, stable heterogeneity
within the HSC-containing population (Dykstra et. al.,
2007). An excellent overview of single HSC transplants, in-
cluding detailed methods, has been previously reported
by Ema et al. (2006).
In our experience, the best source of donor cells in HSC
studies of adult mutant or non-steady-state mice is whole
bone marrow cells. This avoids any problems associated
with potential discrepancy between HSC phenotype and
function and allows an easy way to enumerate the num-
bers of CRU within a set amount of bone marrow, e.g.,
CRU per femur. In our experiments, each recipient mouse
receives cell doses ranging from 83 103 to 23 106 whole
bone marrow cells from our ‘‘unknown’’ source of HSCs
together with 2 3 105 competing congenic bone marrow
(Janzen et al., 2006; Purton et al., 2006; Walkley et al.,
2005a). We have found these cell doses sufficient to
detect both reductions (Purton et al., 2006) and increases
(Janzen et al., 2006;Walkley et al., 2005a) in HSC numbers
in different mutant mice.
Donor Cell Percentage Used to Determine
the Number of Negative Mice
The limiting dilution assay is based on Poisson statistics:
instead of relying on the functional quality of the test
source, the assay relies on the frequency of mice that
are considered to have negative reconstitution by the
test source. The original report by Szilvassy et al. (1990)
transplanted male test cells together with female compet-
ing cells into female recipients, relying on detection of the
Y chromosome by Southern blot analysis. Using this
procedure, they could reliably detect 5% donor (test)
reconstitution; hence, negative reconstitution was defined
as being <5% test-derived cells (Szilvassy et al., 1990).This method is less sensitive than that now obtained by
FACS using congenic transplants, which are now more
routinely used for these assays. It is now more typical to
analyze limiting dilution assays with negative reconstitu-
tion being <1% test cell reconstitution. Some researchers
have even assessed limiting dilution assays with <0.1%
test cell reconstitution being considered to be negative;
however, the accuracy of reliably detecting such low
donor cell reconstitution remains questionable. In all situ-
ations, the test cells should repopulate all lineages, best
assessed by determining the% test-derived cells contrib-
uting to B lymphopoiesis, T lymphopoiesis, and myeloid
(granulocytes and macrophages) cell reconstitution in
the peripheral blood. Peripheral blood erythroid cell
reconstitution cannot be measured using the congenic
system, as mature erythrocytes do not express CD45;
however, it is generally accepted that if the other lineages
are repopulated by the test source, the erythroid lineage
will be as well.
Time Posttransplant at which the Results
Are Analyzed
Another critical contributor to the correct analysis of HSCs
via the limiting dilution assay (which also applies to any in
vivo HSC repopulating assay) is the time point at which the
assays are analyzed. Yang et al. (2005) recently demon-
strated that as few as 50 LKS+ CD34+ Flt3 short-term
repopulating HSCs competed against 2 3 105 congenic
bone marrow cells could reconstitute multiple lineages
(>0.01% myeloid, >1% B and T lymphoid) for at least
16 weeks posttransplant. Furthermore, 50 multipotent
progenitor cells (LKS+ CD34+ Flt3+) could competitively
reconstitute T (>0.01%) and B (>0.1%) lymphopoiesis for
16 weeks, with some myeloid reconstitution also detect-
able at 16 weeks (Yang et al., 2005). These are important
observations, as currently many investigators tend to
report results of long-term HSC assays that are analyzed
at or less than 16 weeks posttransplant. It also raises
the question of whether or not these cells are also
detected in the W41/W41 recipient-based CRU assay, as
these studies have not yet been done.
In addition, an elegant study by Jordan and Lemischka
(1990) analyzed the fate of individual oncoretroviral-
markedHSCs and assessed their contribution tomultiline-
age hematopoiesis posttransplantation. The results
demonstrated that there were frequent fluctuations in
clonal contribution to hematopoiesis for the first 4–
6 months posttransplant, after which a few multipotent
clones gave rise to stable hematopoiesis (6–12 months
posttransplant). These studies suggest that 6 months
posttransplant should be the optimal time point at which
long-term hematopoiesis should be assessed in these
assays. Recent studies byDykstra and colleagues demon-
strate that single cell transplants of putative stem cells can
show gradual decline in reconstituting capacity up until
16 weeks, after which time the contribution was stable,
while other subsets exhibit the opposite reconstitution
kinetics (Dykstra et al., 2007). Therefore, a minimum of
16weeks is required andanoptimal 6months is suggested
for monitoring long-term reconstitution posttransplant.Cell Stem Cell 1, September 2007 ª2007 Elsevier Inc. 267
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Dilution Assays
Cultured Cells
The limiting dilution assay (and other primary competitive
repopulation assays) may not reliably detect HSC content
in cultured cell populations. It is now well-recognized that
there is a hierarchy of HSCs based on their functional
repopulating capacity (Dykstra et al., 2007; Lemischka
et al., 1986a; Purton et al., 2006; Rosendaal et al., 1979;
Yang et al., 2005). Cultured HSCs may represent a range
of HSC potential, depending onwhether the culture condi-
tions have increased the numbers of immature HSCs or
expanded their progeny, which may have better compet-
itive repopulating potential in recipient mice. Hence, in
instances in which cultured cells are used, serial trans-
plant studies should be performed to confirm the conclu-
sions of the primary transplant data, such as shown by
Zhang et al. (2006).
Homing to the Bone Marrow Niche
Limiting dilution assays also do not account for the
homing capacity of the HSCs. Hence, data assessing
HSC content where HSCs have impaired homing capac-
ity, such as calcium sensing receptor null HSCs (Adams
et al., 2006) and HSCs deficient for the Rho GTPase,
Rac1 (Cancelas et al., 2005), may be misleading. In such
instances, conditional mutant mice would be valuable to
study, as deletion of the gene can occur after the HSCs
have been transplanted, hence minimizing any effect of
impaired homing capacity (Cancelas et al., 2005).
Impaired Differentiation of the HSC
into a Hematopoietic Lineage
Another assumption made when utilizing the limiting
dilution assay is that the HSCs have normal differentiation
potential into all lineages. Arrested or impaired differentia-
tion into one or more of the lineages (B lymphocytes,
T lymphocytes, granulocytes/macrophages) could mark-
edly impact the results of the limiting dilution. For exam-
ple, the differentiation of megakaryocytes and lympho-
cytes is severely impaired in conditional AML-1 mice
(Ichikawa et al., 2004). Competitive transplants of bone
marrow from these mice revealed normal contribution to
myelopoiesis at 12 weeks posttransplant but no reconsti-
tution of T or B lymphopoiesis (Ichikawa et al., 2004).
Additional studies of the transplanted mice revealed that
the AML-1-deficient bone marrow showed significant
competitive repopulation of the double negative 2 (DN2)
fraction of immature thymocytes in these mice, but there
was a significant impairment in the contribution of AML-
1-deficient cells to the more mature DN3 thymocytes in
these mice (Ichikawa et al., 2004). In other situations in
which this may occur, investigators can determine lineage
contribution of the HSCs to all of the other lineages aside
from the affected lineage(s), in addition to assessing repo-
pulation of immature progenitor cell content such as in the
studies of Ichikawa et al. described above (Ichikawa et al.,
2004). This may help to determine the correct frequency of
HSCswithin the population. Potential difficulties do arise if
there is a block in myeloid cell production, as both B and T
lymphocytes have long life spans; hence, the limiting dilu-268 Cell Stem Cell 1, September 2007 ª2007 Elsevier Inc.tion assay may not accurately measure HSCs in primary
recipients in such a scenario. In such instances, second-
ary transplants, together with other in vivo and in vitro
studies investigating progenitor cell content as discussed
above may help to delineate whether there is a defect at
the HSC level.
Altered Proliferative Kinetics of Progenitors
The productive capacity of any given stem cell may be
affected by the proliferative kinetics of its descendent pro-
genitor cells. If a progenitor population is capable of
increased proliferation, it may exponentially increase the
production of mature cells that are scored in CRU assays.
It would follow, therefore, that under conditions of limiting
dilution, some animals would be scored positively, not
because of increased HSC numbers, but rather due to
the productivity of their offspring progenitors.
Defects in Hematopoietic Microenvironments
and Their Potential Impact on HSCs
Other defects that may not be accurately assessed using
standard limiting dilution assays include those that occur
when HSCs have an impaired interaction with the bone
marrow microenvironment such as observed for Rac2-
deficient HSCs (Jansen et al., 2005). In such instances,
the increased likelihood of mobilization of the HSCs
away from the HSC niche will impact the results obtained
if using whole bone marrow cells as the test source of
HSCs. Furthermore, microenvironment-specific defects
may contribute to similar phenomena as shown recently
for Rb mutants. Conditional mutant studies have shown
that there are no intrinsic HSC defects in Rb null HSCs
(Walkley and Orkin, 2006). In contrast, loss of Rb in both
the bone marrow microenvironment and myeloid cells re-
sulted in an aberrant microenvironment, which induced
a profound mobilization of HSCs out of the bone marrow
(Walkley et al., 2007b). In the latter instance, the effects
of the microenvironment on HSCs should be assessed
such as we recently reported for RARg null mice, which
also have an impaired microenvironment that markedly
impacts on hematopoiesis (Walkley et al., 2007a).
Method of Detecting Donor versus Host Cells
While the congenic CD45.1/CD45.2 transplant system is
the preferred one for use in assaying murine HSCs, in
some situations investigators are unable to use this sys-
tem due to the donor mouse strains being incompatible
to this system. Backcrossing mice onto the C57BL/6 con-
genic CD45.1/CD45.2 strains is recommended but is also
very time consuming and can delay experiments for more
than 1 year. Hence, in these instances, investigators more
commonly rely on the use of PCR-based techniques (such
as use of the Y chromosome to detect male donor cells in
female hosts) to determine the extent of donor versus host
reconstitution. This can pose issues, especially if the
peripheral blood cells are not fractionated into myeloid
and lymphoid lineages prior to analysis, as lymphoid cells
have a long life span, as discussed above. In these situa-
tions, a more accurate assessment of donor cell-
derived contribution to hematopoiesis may be achieved
by determining peripheral blood myeloid cell reconstitu-
tion in addition to bone marrow-derived immature B
Cell Stem Cell
Protocol Reviewlymphocyte reconstitution in recipient mice at 6 months
posttransplant.
Concluding Remarks
In conclusion, while remaining one of the better assays to
assess HSC content, investigators should also be aware
of the potential problems associated with analyzing limit-
ing dilution assays. Caution should also be taken when
forming conclusions based on data obtained using
shorter-term approaches commonly used to analyze
HSC content. It is recommended that investigators
assessing HSC content in mutant and nonsteady state
populations use long-term in vivo-repopulating assays
together with a range of the other short-term in vitro and
in vivo assays to accurately determine the number and
functional potential of HSCs and their progenitors in
mice. Furthermore, the recommended 16–26 weeks post-
transplant required for analysis have cost implications that
are obvious and extremely problematic. Finally, the long
interval required for analysis of these assays impedes
progress in the field. Alternative means of assessing and
quantitating HSCs are clearly needed but may be more
of a dream than a reality.
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